Sandoz, a generic and biosimilar medicines company, has signed an agreement to acquire the U.S. biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc. for $170 million up front. This is inclusive of a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, as well as access to proprietary commercial software.
 
Keren Haruvi, President Sandoz North America, said, “I am pleased that we can add another high-value product to the growing Sandoz biosimilar portfolio, further strengthening our existing ophthalmology franchise. The addition of CIMERLI reinforces our commitment to biosimilars and represents a huge step towards our goal of pioneering patient access to more affordable and much-needed medicines in the U.S.”
 
The agreement to acquire the CIMERLI business from Coherus expands Sandoz’s ophthalmic platform that would support future product launches.